Revolutionizing Healthcare | The Cognitive Diagnostics Market's Cutting-Edge Technologies

According to the most recent industry analysis from Future Market Insights, Global Cognitive Diagnostics Market Sales are predicted to reach US$ 110.2 Billion in 2023, with a CAGR of 8.0% over the forecast period, reaching an estimated worth of US$ 238.3 Billion by 2033.

Brain difficulties or cognitive disorders can be caused by closed head injuries, interactions with neurotoxins (toxic substances), genetics, infections, strokes, and tumours. Depending on whether portion of the brain is affected, a person may have a certain type of cognitive difficulty. Communication issues could be caused by a tumour in the brain's speech cisterns, for example. A brain infection that destroys the motor recentres, for example, might cause movement problems. Age has an impact on the development of cognitive impairments.

Wearables and smartphone apps are becoming more popular in cognitive diagnostics. These devices can monitor a patient's cognitive health and send real-time data to medical professionals for more accurate diagnosis and management.

In the market for cognitive diagnostics, collaboration and collaborations between academic institutions, technological firms, and healthcare providers are increasing. Collaborations like these can foster creativity, provide access to technology and approaches for identifying cognitive deficits, and hasten the discovery of novel treatments for these illnesses. For example, in June 2022, the Davos Alzheimer's Collaborative awarded Avant Institute, in partnership with COGNIVUE, a grant to build an innovative Alzheimer's disease early detection programme.

Key Players

  • Cognetivity Neurosciences
  • Cognivue, Inc.
  • Cogstate Ltd.
  • Cambridge Cognition Ltd.
  • Diadem srl
  • CN Diagnostics

Get More Insights@ https://www.futuremarketinsights.com/reports/cognitive-diagnostics-market

Key Market Segments Covered in the Cognitive Diagnostics Industry Research

Diagnosis:

  • Brain Imaging Tests
    • Magnetic Resonance Imaging (MRI)
    • Computerized Tomography (CT)
    • Positron Emission Tomography (PET) and PET/CT
  • Laboratory Testing
    • Cerebrospinal fluid (CSF)
    • Blood Tests
  • Mental Status Testing
    • Mini-Mental State Exam (MMSE)
    • Montreal Cognitive Assessment (MoCA)
  • Rapid Home Screening Tests
  • Neuropsychological Testing
  • Electroencephalogram (EEG)
  • Cognitive Function & Behavioral Tests
  • Neuropsychiatric Inventory Questionnaire (NPI-Q)

Indication:

  • Alzheimer’s disease
  • Attention deficit/hyperactivity disorder
  • Dementia
  • Epilepsy-Related Cognitive Dysfunction
  • Mild Cognitive Impairment
  • Parkinson’s Disease-related Cognitive Dysfunction
  • Stroke-related Cognitive Dysfunction
  • Traumatic Brain Injury
  • Others

End User:

  • Hospitals
  • Neurology Clinics
  • Cognitive Behavioral Therapy Centers
  • Rehabilitation Centers
  • Academic and Research Institutes
  • Diagnostic Imaging Centers
  • Home Care Settings

Comments

Post a Comment

Popular posts from this blog

Handheld Ultrasound Scanners Market Will Generate Booming Growth Opportunities to 2032

Image
According to industry predictions, the global Handheld Ultrasound Scanners Market Demand will increase at a CAGR of 9.1% from 2022 to 2032, reaching a value of US$ 472.1 million by the end of 2022. By 2032, sales are estimated to exceed a valuation of roughly US$ 1.1 billion. With an expected 83.6% market share in 2021, the wired modality now leads the sector. Because they connect to Bluetooth or Wi-Fi devices such as mobile phones or tablets, Handheld Ultrasound Scanners are gaining appeal among both medical professionals and non-radiologists. These devices improve networking systems and ease picture transfer to medical facilities. Global Handheld Ultrasound Scanners Market: Dynamics         Technological advancements in medical imaging devices, increased use of Handheld Ultrasound Scanners among non-radiologists, benefits from international trade agreements, increased importing of imaging diagnostics systems, increased use of Handheld Ultrasound Scanners in emergency medical service
Read more

Targeted Therapies for Sandhoff Disease | Assessing the Global Market Landscape

Image
The global Sandhoff Disease Therapeutics Market Size is expected to be worth US$ 10 million in 2023 and US$ 17.91 million by 2033, with a CAGR of 6% from 2023 to 2033. From 2018 to 2022, the Sandhoff Disease Treatments market increased at a 4% CAGR. According to the most recent studies, Sandhoff sickness is a rare disorder that affects 1 in 1,000,000 people. The rising demand for these medications is projected to spur the discovery of novel therapies, propelling the market forward in the coming years. Gene therapy is being investigated as a potential treatment for Sandhoff disease. The therapy restores the ability to break down GM2 ganglioside by delivering a functional copy of the missing enzyme into the patient's cells. This has the potential to reduce or stop disease progression while also improving patient quality of life. Key Takeaways from the Market Study   The Sandhoff Disease Therapeutics market increased at a 4% CAGR from 2018 to 2022. From 2023 to 2033, the global Sandh
Read more

Antidiabetics Market to reach US$ 223 billion by 2032, growing at a 9.6% CAGR from 2022 to 2032 | Future Market Insights, Inc.

Image
The global Antidiabetics Market is expected to earn US$ 223 billion while expanding at a CAGR of 9.6% during the forecast period. The rising prevalence of diabetes worldwide can be attributed to the market's expansion. The ageing baby boomer population is another factor driving the market during the forecast period. According to the International Diabetes Federation, the global diabetes incidence will increase from 366 million in 2011 to 552 million by 2030. During the forecast period, the industry is expected to benefit from a significant increase in the number of diabetic patients. Furthermore, new product development is expected to benefit the market in the near future. For example, Novo Nordisk, a Danish pharmaceutical company, announced the launch of oral semaglutide for the treatment of Type 2 diabetes in India in January 2022. Furthermore, the development of advanced pumps based on smart technologies like AI and ML is expected to open up a slew of new doors. For exampl
Read more